News Articles and Montana BioScience Alliance Newsletters
Viral clearance testing is a critical step in the development and production of biologics and other products that are derived from biological sources. GMP-compliant service provides the assurance that products have been thoroughly tested for the presence of viral contaminants, and that they are safe for use.
Scientists at the McLaughlin Institute are spearheading this patient registry which allows the Institute to enroll Montanans in potential clinical trials and research studies.
On January 12, 2023, the Montana High Tech Business Alliance and the Montana Bioscience Cluster Initiative co-hosted the webinar “Scaling Biotech Companies in Montana.” Panelists shared their insights into how companies can effectively plan for growth and how Montana can scale its biotech ecosystem.
A University of Montana research center recently was awarded a $480,000 grant to support the purchase of a three-dimensional bioprinter, which will allow nanofabrication of tiny structures.
Five UM public health master’s students working on projects that tackle some of the largest health issues facing the state and region recently earned the regional Student Leaders in Public Health Award from the Rocky Mountain Public Health Training Center in the Colorado School of Public Health. The award provides $3,500 to each project.
Are you working to develop an innovative cancer technology? Take a step forward in your commercialization journey through the newly released FY2024 SBIR Contract Solicitation! This funding opportunity aims to provide early-stage funding to small businesses that are developing cancer technologies in areas defined by the National Cancer Institute.
The U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s Disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit.
The PHS 2023-2 omnibus solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications have been released. The first application due date is Tuesday, September 5, 2023.
The panel’s decision moves the U.S. one step closer to making jabs against respiratory syncytial virus available to the public this fall, when the disease typically begins to spread at higher levels.
The biennial report provides a national snapshot of the most pressing current and anticipated talent needs of the nation’s dynamic life science industry. This year’s report distills a set of key themes sourced from 185 executive interviews and nearly 700 survey responses from companies in eighteen states and Puerto Rico, as well as an assessment of nearly 2.8M job postings from life science companies over the last four years.